Clinical Trial

An Observational Study on Predicting the Efficacy of Immunotherapy for NSCLC Based on LIRAscore

Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated January 30, 2024 (before its estimated August 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a multi-center, observational clinical study to explore the role of LIRAscore in predicting immunotherapy monotherapy and combination with chemotherapy efficacy and prognosis in locally advanced or metastatic non-small-cell lung cancer. The study plans to enroll 108 patients. The primary endpoint of this study was ORR, and secondary endpoints were PFS, OS, DoR, DCR, and safety.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT06232265
Lead Sponsor Nanfang Hospital, Southern Medical University
Conditions Non-small Cell Lung Cancer
Enrollment 108 participants
Start Date 2023-09-22
Primary Completion 2025-08-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2024-01-30